ADAM17 and COVID-19: Altogether, it is implied that the rise in sACE2 in COVID-19 is the result, not the cause, of SARS-CoV-2-induced activation of a cascade of proinflammatory pathways accompanied by ADAM-17 stimulation which lead to the release of mACE2 as a soluble form into the circulation.